China SXT Pharmaceuticals, Inc. income statement SXTC

Annual Quarterly

In fiscal 2026, which ended Mar 31, 2026, China SXT Pharmaceuticals, Inc. reported revenue of $1.1 million, down 34.6% from the year before. It recorded a net loss of $6.2 million. The operating loss came to $7.1 million, an operating margin of -625.9%. Diluted earnings per share were -$9.13. Across the 8 fiscal years shown, revenue shrank from $7.0 million in fiscal 2019 to $1.1 million in fiscal 2026, about 22.9% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2026 Mar 31, 2026	FY 2025 Mar 31, 2025	FY 2024 Mar 31, 2024	FY 2023 Mar 31, 2023	FY 2022 Mar 31, 2022	FY 2021 Mar 31, 2021	FY 2020 Mar 31, 2020	FY 2019 Mar 31, 2019
Revenue	1 -34.6%	2 -9.7%	2 -2.2%	2 -24.2%	3 -45.5%	5 -7.5%	5 -26.4%	7
Cost of revenue	1 -35.2%	1 -0.1%	1 -11.1%	2 +14.4%	1 -30.3%	2 -21.2%	2 +2.4%	2
Gross profit	0 -32.3%	0 -33.7%	1 +30.0%	0 -65.9%	1 -55.9%	3 +5.0%	3 -41.4%	5
Research and development	—	—	0	—	—	—	—	—
Selling, general and administrative	7 +141.9%	3 -0.7%	3 -49.1%	6 +7.5%	6 +11.5%	5 +24.5%	4 +42.3%	3
Other operating income (expense)	1 +3815.7%	0 +164.2%	-0	—	—	—	—	—
Operating income	-7 -165.7%	-3 -6.6%	-3 +55.1%	-6 -8.1%	-5 -136.2%	-2 -63.8%	-1 -175.8%	2
Other income (expense)	1 +247.3%	-1 -6.8%	-1 -78.2%	-0 -49.9%	-0 +70.7%	-1 +91.8%	-9 -41291.2%	0
Pretax income	-6 -87.8%	-3 -6.6%	-3	—	-5 -83.9%	-3 +71.7%	-10 -680.0%	2
Income tax	—	—	—	—	0 +270.3%	-0 -89.4%	-0 -140.3%	0
Net income	-6 -87.8%	-3 -6.6%	-3 +47.8%	-6 -3.5%	-6 -108.7%	-3 +73.3%	-10 -768.4%	2
Basic EPS	-9.13 +97.4%	-348.17 +91.9%	-4,285.66 -2309.9%	-177.84 -28.9%	-137.92	—	—	0.07
Diluted EPS	-9.13 +97.4%	-348.17 +91.9%	-4,285.66 -2309.9%	-177.84	—	—	—	0.07
Weighted average shares, basic	1 +7062.5%	0 +1212.4%	0 -97.8%	0 -19.8%	0	—	—	21
Weighted average shares, diluted	1 +7062.5%	0 +1212.4%	0 -97.8%	0	—	—	—	21
Other measures
Depreciation and amortization	0 -10.5%	0 -59.5%	0 -18.8%	0 -21.8%	0 -7.4%	0 +4.1%	0 +90.7%	0
EBITDA	-7 -171.3%	-3 -12.4%	-2 +56.8%	-5 -10.0%	-5 -163.0%	-2 -83.5%	-1 -151.9%	2
Interest coverage	-113.13x	-4.14x	-4.62x	—	—	—	—	—
Margins
Gross margin	21.85%	21.11%	28.73%	21.62%	48.10%	59.43%	52.37%	65.77%
Operating margin	-625.89%	-153.97%	-130.42%	-284.40%	-199.43%	-45.99%	-25.98%	25.24%
Pretax margin	-545.24%	-189.77%	-160.67%	—	-207.82%	-61.56%	-201.26%	25.55%
Profit margin	-545.24%	-189.77%	-160.67%	-301.00%	-220.43%	-57.52%	-199.29%	21.95%
EBITDA margin	-619.42%	-149.24%	-119.88%	-271.71%	-187.13%	-38.76%	-19.55%	27.72%
Effective tax rate	—	—	—	—	—	—	—	14.08%

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: SXTC (Nasdaq)
Fiscal year ends: March 31
Incorporated in: Virgin Islands, British
Headquarters: Taizhou
SEC filer status: Non-accelerated filer
SEC CIK: 1723980

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.